Galena Biopharma to Host Webcast and Conference Call Today
July 08 2016 - 7:35AM
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company
committed to the development and commercialization of targeted
oncology therapeutics that address major unmet medical needs, today
announced the Company will host a conference call this morning to
discuss today’s financing, the interim analysis on the Phase 3
trial, and provide an update on the Company’s clinical development
programs.
The webcast and conference call will take place today at 9:00
a.m. P.T./12:00 p.m. E.T.
The webcast can be accessed on the Company's website under the
Investors section/Events and Presentations:
http://investors.galenabiopharma.com/events.cfm.
The conference call can be accessed by dialing (844) 825-4413
toll-free in the U.S., or (973) 638-3403 for participants outside
the U.S. The Conference ID number is: 46864387.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed
to the development and commercialization of targeted oncology
therapeutics that address major unmet medical needs. Galena’s
development portfolio is focused primarily on addressing the
rapidly growing patient populations of cancer survivors by
harnessing the power of the immune system to prevent cancer
recurrence. The company’s pipeline consists of multiple
mid-to-late-stage clinical assets, including novel cancer
immunotherapy programs with NeuVax™ (nelipepimut-S) and
GALE-301/GALE-302, and one hematology program, GALE-401. For more
information, visit www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to,
statements about the progress of the development of Galena’s
product candidates, patient enrollment in our clinical trials, as
well as other statements related to the progress and timing of our
development activities, present or future licensing, collaborative
or financing arrangements, expected outcomes with regulatory
agencies, and projected market opportunities for product candidates
or that otherwise relate to future periods. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including those identified under “Risk Factors” in
Galena’s Prospectus Supplement filed July 7, 2016, Annual Report on
Form 10-K for the year ended December 31, 2015 and most recent
Quarterly Reports on Form 10-Q filed with the SEC. Actual results
may differ materially from those contemplated by these
forward-looking statements. Galena does not undertake to update any
of these forward-looking statements to reflect a change in its
views or events or circumstances that occur after the date of this
press release.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
ir@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024